Best Grants for Cancer Nonprofits in Delaware

The Cancer Prevention and Control Programs aim to enhance cancer outcomes by funding partnerships among national, state, territorial, and tribal organizations. These initiatives focus on evidence-based strategies for cancer surveillance, prevention, and control, specifically targeting breast and cervical cancer screening for underserved populations. Through collaboration, the program seeks to improve clinical services and cancer survivorship, ultimately striving towards the vision of 'All People Free of Cancer' by leveraging resources and community involvement.

About Pfizer Grants

Pfizer supports the global healthcare community’s independent initiatives (e.g., research, quality improvement or education) to improve patient outcomes in areas of unmet medical need that are aligned with Pfizer’s medical and/or scientific strategies.

Interventional Research Studies of Brentuximab Vedotin-Based Novel Combinations in AITL and PTCL-NOS

This competitive program is designed to support interventional InvestigatorSponsored Research aimed at generatin clinical evidence for brentuximab vedotin in novel combination approaches in angioimmunoblastic T-cell lymphoma (AITL) and peripheral T-cell lymphoma–not otherwise specified (PTCL-NOS).

Project Types and Area of Interest

Studies considered for Pfizer support should address key clinical and scientific gaps in the use of brentuximab vedotin in AITL and PTCL-NOS irrrespective of CD30 expression, with a focus on evaluating the safety and efficacy of novel brentuximab vedotin–based combinations with therapies available for PTCL treatment that are supported by a clear scientific rationale grounded in mechanism of action and/or disease biology.

About Us

Children’s Cancer Research Fund is a national nonprofit dedicated to ending childhood cancer. Our main focus is to support the research of bright scientists across the country whose ideas can make the greatest impact for children fighting cancer. We also fund resources and programs that help kids and families as they navigate the difficult experience of cancer treatment and survivorship.

Since 1981, we’ve contributed over $235 million to research, support programs for children and families, and awareness and education outreach. In 2024, over 81 percent of funds raised went directly to these program services areas.

Children’s Cancer Research Fund (CCRF) is a national nonprofit committed to finding safer, more effective therapies for kids battling cancer. Thanks to donors and partners around the country, we have contributed over $235 million to research, education and awareness, and quality-of-life programs for childhood cancer families. We believe kids deserve safer, less toxic treatments, and we’re committed to funding groundbreaking research and services that enhance healing and care.

In 2026, Children’s Cancer Research Fund will focus our research funding efforts on three main areas:

• Hard-to-Treat Cancers
• Survivorship
• Health Disparities

Accelerating Hope: Clinical Trials for Hard-to-Treat Cancers Award

This funding opportunity is limited to support for clinical trials focused on hard-to-treat cancers, prioritizing Phase 0 – Phase 2 studies. Learn more about eligibility criteria and other key details below.

The Healthy After Cancer Award, offered by the Children's Cancer Research Fund, focuses on enhancing the quality of life for childhood cancer survivors. This funding supports research aimed at addressing the long-term effects of cancer therapy, prioritizing survivorship interventions over new treatment development. With a commitment to improving health outcomes for young survivors, this award underscores the importance of addressing unique challenges faced by this population.

The Eliminating Disparities in Childhood Cancers Award, offered by the Children’s Cancer Research Fund, supports innovative research aimed at reducing health disparities in childhood cancer. This initiative prioritizes proposals that identify modifiable risk factors and mechanisms of disparities, emphasizing the importance of improving access to care and treatment outcomes. With over $235 million invested since 1981, CCRF is dedicated to enhancing the quality of life for children and families affected by cancer.

The Accelerating Impact for Hard-to-Treat Cancers Award, offered by the Children's Cancer Research Fund, focuses on pre-clinical research to enhance treatment outcomes for pediatric cancers that are difficult to treat. The award supports innovative studies, including pilot projects and the development of new technologies. As a nonprofit, CCRF has invested over $235 million in initiatives since 1981, aiming to improve therapies and support for children battling cancer, thereby fostering safer and more effective treatment options.

Pershing Square Lotus Award for Ovarian Cancer Research

The Pershing Square Foundation (PSF) has worked across sectors to catalyze innovative approaches to the most difficult problems. Talented individuals have always been at the center of our approach. We aim to support leaders who transform systems, embrace new paradigms, and have an innate drive to make an impact.

PSF has funded pioneering cancer researchers through the Pershing Square Sohn Cancer Research Alliance for over a decade and supported women’s health initiatives in New York City. Through this Request for Proposals (RFP), PSF aims to combine these two priority areas of women’s health and cancer to shine a light on one of the most understudied and underfunded cancers—ovarian cancer. Ovarian cancer is the deadliest gynecologic cancer, with 80% of women diagnosed at an advanced stage. Only 27% of women diagnosed during an advanced stage survive for five years. Ovarian cancer remains a disease with a poor prognosis due to limited early detection and treatment options.

PSF supports research efforts by 

• deploying capital quickly, 
• funding high-risk, high-reward ideas, 
• bringing new perspectives into a field, 
• encouraging collaboration, and 
• leveraging our vast network. We challenge our scientific partners to think creatively and across silos, to spur innovation to fight ovarian cancer.

Through the Pershing Square Lotus Award for Ovarian Cancer Research, PSF is looking for investigators who are either already working on a promising project in ovarian cancer or in another type of cancer that could have an impact on ovarian cancer. Grantees each receive $250,000 a year for three years, totaling $750,000.

Researchers who are not studying ovarian cancer are encouraged to apply and required to find a collaborator with experience in ovarian cancer research.

This award aims to 

• inspire investigators with unique expertise to apply their knowledge to ovarian cancer and 
• empower ovarian cancer researchers to pursue their boldest, most innovative ideas. Facing a disease where too few have survived to-date, PSF ultimately aims to create a culture around ovarian cancer that offers women hope, akin to the breast cancer community. PSF is passionate about changing outcomes for tens of thousands of women a year and is hopeful that future scientific discoveries will allow for more survivors who can share their stories for years to come.

Mesothelioma Applied Research Foundation Inc

The Mesothelioma Applied Research Foundation is the only nonprofit charity organization dedicated to ending mesothelioma, and the suffering caused by this cancer, by:

• funding research to improve treatment options;
• providing treatment support and education for patients and their families;
• and advocating for federal funding of research.

The mission of the Mesothelioma Applied Research Foundation spans across four distinct areas: through research, education, support, and advocacy the Foundation seeks to eradicate the vicious effects of mesothelioma. Led by the Board of Directors, our team works collaboratively to develop and administer our programs, and to fundraise to pay for those programs (the Foundation is funded by private individual and corporate contributions only — it does not receive any government funding).

Patient Travel Grant Program

A mesothelioma diagnosis and treatment often require the patient and their family to incur numerous expenses as part of their treatment. Travel to treatment, alone, can cause a significant financial burden on the patient, which might even cause the patient to not seek treatment away from home, even it’s their best option. To ensure that all patients have the ability to seek specialized help and treatments, the Mesothelioma Applied Research Foundation administers its Travel Grant Program.

The Meso Foundation’s Patient Travel Grant Program, founded by Mary and Bob Cosentino, provides travel grants to patients and one caregiver traveling for an initial consult and/or for clinical trial treatments.

• The type of eligible travel must fall into at least one of these two categories:
  • One trip for one initial consultation with a mesothelioma specialist.
  • Multiple trips to participate in an interventional clinical trial (found on clinicaltrials.gov).

Mesothelioma Applied Research Foundation Inc

The Mesothelioma Applied Research Foundation is the only nonprofit charity organization dedicated to ending mesothelioma, and the suffering caused by this cancer, by:

• funding research to improve treatment options;
• providing treatment support and education for patients and their families;
• and advocating for federal funding of research.

The mission of the Mesothelioma Applied Research Foundation spans across four distinct areas: through research, education, support, and advocacy the Foundation seeks to eradicate the vicious effects of mesothelioma. Led by the Board of Directors, our team works collaboratively to develop and administer our programs, and to fundraise to pay for those programs (the Foundation is funded by private individual and corporate contributions only — it does not receive any government funding).

Bret A. Rosenthal Patient Assistance Fund

Patients diagnosed with cancer at a younger age often face greater financial burdens. This is a time in a patient’s life when they are raising a family, starting a career, or have not accumulated savings. For patients 49 and under, the Foundation administers the Bret A. Rosenthal Patient Assistance Fund grant program. This program is made possible by the generosity of the Rosenthal family.

The Cancer Prevention and Control Programs aim to eliminate cancer through collaborative efforts among state, territorial, and tribal organizations. Funded by the CDC, this program supports initiatives such as breast and cervical cancer screening, cancer control planning, and cancer surveillance. By fostering partnerships and community involvement, the program seeks to improve health outcomes and achieve the mission of 'All People Free of Cancer.' This comprehensive approach ensures that resources are effectively coordinated to address the cancer burden in communities.

American Cancer Society

The mission of the American Cancer Society is to improve the lives of people with cancer and their families through advocacy, research, and patient support, to ensure everyone has an opportunity to prevent, detect, treat, and survive cancer.

ACS Research Priority Areas

The American Cancer Society (ACS) has identified these 6 areas to categorize and track the research we fund to help advance our mission. Applicants (except Institutional Research Grants and Professor grants) are asked to select at least 1 of these research areas that aligns with their proposal:

• Etiology (causes of cancer)
• Obesity/Healthy Eating and Active Living (HEAL)
• Screening and Diagnosis
• Treatment
• Survivorship
• Health Equity Across the Cancer Continuum

Research Scholar Grants

Research Scholar Grants (RSG) provide support for independent, self-directed researchers.

Applicants' institutions must provide space and other resources customary for independent investigators.

Grant proposals are investigator-initiated and may pursue questions across the cancer research continuum, as long as they fit within an American Cancer Society (ACS) priority research area.

These grants typically contribute to the cost of salaries, consumable supplies, and other miscellaneous items required in the research. 

Research Scholar Grants are funded up to $215,000 per year (direct costs), plus 10% allowable indirect costs, with a project period up to four years.

This funding opportunity aims to enhance the cancer surveillance workforce through education and support for certified Oncology Data Specialists. The initiative will improve the quality and completeness of cancer data collected by the National Program of Cancer Registries. By fostering collaboration and promoting the value of cancer surveillance data, this program seeks to empower public health actions, research, and policy-making, ensuring a robust response to current and future cancer-related challenges.

The Canine Cancer Immunotherapy Network (K9CIN) aims to advance canine cancer treatments through innovative clinical trials, paralleling the development of human therapies. This initiative is vital as pet dogs naturally develop cancer, mirroring human responses to treatments. By leveraging NIH support, K9CIN will facilitate research to enhance immunotherapeutic strategies for both dogs and humans, fostering a collaborative environment for veterinary and human medical advancements. Ultimately, this funding opportunity promotes ethical research that benefits both species.

Nurses Educational Funds

Nurses Educational Funds, Inc. depends solely on donations to advance our only mission, to promote nursing leadership through annual scholarship support for professional nurses seeking masters and doctoral degrees in nursing education, practice, research, and administration.

NEF’s only purpose is to provide nursing scholarship assistance to make graduate level nursing education possible. NEF is one of the largest, national, private, professionally endorsed source of funds for advanced nursing study with over one hundred years of service to and for professional nursing. NEF is a non-profit organization with 501(c) status.

Martha Rodriguez Scholarship Fund

Martha Rodriguez Memorial Scholarship was initiated in 2025 by Lisa Ackerman, close friend and then Director of the Columbus Citizens Foundation. Raised in Gary, Indiana and a true New Yorker, Martha died as the result of traumatic head injuries from a tragic accident just outside her NYC apartment. Martha Rodriguez gave in life, working as a nurse helping patients navigate the trauma of breast cancer at Memorial Sloan Kettering Cancer Center. In her death, she was lauded by the President of LiveOnNY, an organization that coordinates and oversees organ donations, for her last selfless act of giving. Martha donated organs that gave life and hope and helped three people lead better lives. Her zest for life was contagious, and her dedication, compassion, and expertise left an indelible mark on the lives of countless MSKCC patients and caregivers. She was a friend and mentor to many. She loved being a nurse at MSKCC and worked for more than 28 years as a nurse practitioner and for the last 15 years of her life dealing with breast cancer patients. This scholarship is awarded to nurses studying in master's or doctoral programs who are dedicated to oncology care, or women’s health, or are Latinx nurses.

The Community Foundation’s scholarships are for Arkansas students pursuing education at two- or four-year colleges or universities, vocational schools or technical training programs. Each scholarship has its own eligibility criteria. Some scholarships are designated for graduates of a particular high school or those who plan to attend a particular college. Others are based on extracurricular activities or intended college majors.  

The Foundation has a scholarship portal with a quiz to help applicants determine scholarship eligibility. 

“Since 1976, the Community Foundation has partnered with individuals and organizations who want to support our state’s students in their pursuit of higher education,” said Heather Larkin, Community Foundation president and CEO. “These generous people provide the funding and determine the size and eligibility criteria of each scholarship, while we oversee the application and awarding process on their behalf.”  

Ryan Mondy D.A.S.H. Memorial Scholarship

Provides scholarships to graduating seniors whose lives have been affected by cancer.

We administer a number of scholarships, which range from the traditional academic and athletic awards to corporate and special circumstances offerings. Applying for a scholarship is free, so we invite you to spend some time finding opportunities for which you are a good fit.

Ounce of Prevention Scholarship Fund

The purpose of the fund is to provide one or more annual scholarships to graduates of an accredited high school located in Marshall County, Indiana.  

Recipients must be a survivor of cancer, have an immediate family member or friend who experienced cancer, or have demonstrated active participation in community service related to the prevention or cure of cancer.

Alliance for Cancer Gene Therapy

Unlike surgery, chemotherapy and radiation, cell and gene therapies harness the power of your immune system to destroy cancer cells without harming healthy tissue. We fund the research that will make this vision a reality.

Collaborating with partners and funding research fellows, we are transforming cancer treatments today while bringing the world closer to a cure for all cancers tomorrow.

ACGT Investigator Award in Cell and Gene Therapy for SOLID TUMOR CANCERS 

Purpose

Alliance for Cancer Gene Therapy, Inc. (ACGT) funds breakthrough research that is transforming cancer treatment through cell and gene therapy. This ACGT grant award is for those conducting translational cell and gene therapy research specifically in solid tumor cancers.

Research Objectives

Cell and gene therapy for solid tumors poses major challenges driven by antigen heterogeneity, physical exclusion, immunosuppressive microenvironments, genomic instability, and safety limitations. This RFA seeks innovative, translational cell and gene therapy strategies that directly address these barriers.

Proposed approaches should demonstrate the capacity to: (1) overcome antigen escape through multi-targeted designs that broaden patient populations and account for heterogeneity and resistance due to antigen loss; (2) enhance trafficking, infiltration, and persistence within solid tumor sites; (3) resist or reprogram the immunosuppressive tumor microenvironment; and (4) incorporate built-in safety and controllability mechanisms suitable for clinical translation. Successful proposals will integrate these elements to enable durable, precise, and scalable therapeutic impact in solid tumors.

Building on the priorities outlined above, this RFP encourages proposals spanning a broad range of cell and gene therapy (CGT) platforms and rational combinations, including but not limited to:

• Engineered T Cell Approaches
• Innate and Alternative Immune Cell Platforms
• Gene Editing & Synthetic Biology Strategies
• Microenvironment-Modulating Strategies
• Combinatorial Approaches

Proposals that integrate multiple strategies to overcome trafficking, suppression, antigen escape, and safety barriers in a coordinated manner are strongly encouraged. Preference will be given to approaches with clear mechanistic rationale and a credible path toward clinical translation in solid tumors.

The Juan Diego Guadiana Legacy Foundation Scholarship supports students from Las Cruces High School or Doña Ana County, especially those affected by cancer treatment or pursuing health-related fields. This scholarship is open to various backgrounds, including BiPOC and LGBTQIA+ communities. The foundation aims to empower students at different educational stages, ensuring they have the resources necessary to thrive in their academic and professional journeys.

The NCI Research Specialist Award (R50) supports clinician scientists involved in NCI-funded clinical trials. This funding opportunity encourages the development of stable research careers by providing salary support and autonomy, allowing clinician scientists to contribute to national clinical trial development and implementation. They play a critical role in sustaining the NCI clinical trials network without serving as principal investigators. This award aims to ensure continuity in cancer research careers.

The NCI Research Specialist Award (R50) supports non-tenure track scientists in cancer research who provide essential contributions within laboratories and core facilities. This award aims to enhance research careers for skilled scientists who do not seek independent investigator funding. Eligible candidates must possess an advanced degree, have at least two years of contribution to NCI-funded research, and dedicate a significant portion of their time to this work. The R50 offers salary support and travel funds to recognize and stabilize these vital roles in cancer research.

Improving Metastatic Prostate Cancer (mPCa) Care Through Innovative Strategies

The National Comprehensive Cancer Network® and Pfizer Global Medical Grants (Pfizer) are collaborating to offer a new grant opportunity seeking proposals for investigator-initiated research to improve mPCa care. Pfizer (hereafter, “Grantor”) is providing $1 Million in funding to support quality improvement studies to advance health care quality, the delivery of quality care, and improve health care provider performance in mPCa care. The Grantor will serve as the funding organization. Grants are available to all investigators from institutions within the United States. 

Aim

To promote the advancement of scientific knowledge, health care provider performance, and/or health care quality improvement focused on improving mPCa care.

A total of $1 Million is available to fund all projects. The intent is to fund 2-5 studies. There is a funding cap of $250,000 per study. Exceptional studies with budgets above this amount will be considered based on scientific merit and must contain a robust justification. All budgets must include line-item information and robust justification.

The Radiation Oncology-Biology Integration Network (ROBIN) Centers, funded by the National Cancer Institute (NCI), aims to enhance national radiation oncology infrastructure through collaborative research. This initiative supports studies on biological responses to radiation treatment in cancer patients, focusing on understanding tumor and tissue changes. By integrating various scientific disciplines and collecting comprehensive data, ROBIN intends to improve cancer care, optimize treatment strategies, and accelerate translational discoveries to enhance patient outcomes.

The Paul Calabresi Career Development Award for Clinical Oncology aims to enhance the training of clinician-scientists in clinical and translational cancer research. This funding opportunity encourages the career growth of researchers but does not permit Scholars to lead independent clinical trials. Instead, it allows participation in clinical trials under the mentorship of an experienced researcher, fostering a collaborative approach to cancer research.

The DoW Rare Cancers Idea Development Award promotes innovative research ideas for rare cancers, encouraging applicants to provide preliminary data and exploratory aims. This funding opportunity, offered by the US DOD: U.S. Army Medical Command, seeks projects with the potential for high-impact findings that can significantly benefit the patient community. It aims to foster new avenues of investigation and support discovery-driven research in the field of rare cancers.

The 2026 Rare Cancers Research Program Resource and Community Development Award aims to enhance rare cancer research through improved resources and datasets. It addresses critical gaps in research resources, communication strategies, and data sharing infrastructures. Key features include engaging patient advocates throughout the research process and ensuring sustainability of community platforms. This funding opportunity emphasizes community building and the dissemination of findings to benefit scientific and patient communities alike.

The National Cancer Institute (NCI) invites applications for innovative technologies aimed at cancer research and clinical care. This funding opportunity supports early-stage projects focused on proof-of-concept studies to assess the feasibility of new methods and tools. Applications should demonstrate significant technical innovation, targeting advancements in cancer biology, early detection, clinical diagnosis, treatment, and epidemiology. Technologies may include novel analysis platforms, imaging technologies, and biospecimen processing innovations, with a focus on cancer applications.

The National Cancer Institute (NCI) invites applications for the R33 grant aimed at advancing emerging technologies in cancer research. This funding opportunity seeks projects that demonstrate significant progress in technology development, focusing on cancer biology, early detection, and clinical diagnosis. Eligible proposals must showcase innovative methodologies that enhance research capabilities, with a strong emphasis on technical validation and broad applicability in cancer applications.